Friday, July 10, 2026

pharma · Non Small Cell Lung Cancer · Locally Advanced Solid Tumor · TNGX

Tango Therapeutics

Tango Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker TNGX. Primary therapeutic focus areas include Non Small Cell Lung Cancer, Locally Advanced Solid Tumor, MTAP-delete

Boston, USA HQ
2017 Founded
154 Employees
Public company Type
TNGX · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Founded
2017
Employees
154
Programs
7
Drugs
2
Patents
9
Clinical program

TNG908-C101

Phase 2 · small molecule · "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

TNG908-C101 for "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM" is a Phase 2 program (small_molecule) at Tango Therapeutics with 1 ClinicalTrials.gov record(s).

← All Tango Therapeutics projects Phase 2 small molecule active

Internal code TNG908-C101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Tango Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
"Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"
Status
active
Trials
1